Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELATIVITY-022: Relatlimab +/- Nivolumab in B-Cell Malignancies
NCT02061761Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
Phase 2, open-label trial of relatlimab in chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and 2 more (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation up to 51 months, Number of Participants Who Died up to 52 months and 3 more. Started Mar 2014; status: completed.
02
Drugs
relatlimab
03
Conditions
chronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02061761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061761.